CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
U.S. Feraheme product sales, net	$ 19,347	$ 16,186	$ 52,381	$ 43,906
License fee and other collaboration revenues	1,998	1,566	6,056	19,911
Other product sales and royalties	271	(10)	708	417
Total revenues	21,616	17,742	59,145	64,234
Costs and expenses:
Cost of product sales	2,547	4,323	8,634	10,193
Research and development expenses	4,530	5,260	13,983	25,393
Selling, general and administrative expenses	14,934	12,160	44,150	40,442
Restructuring expenses		562		1,620
Total costs and expenses	22,011	22,305	66,767	77,648
Other income (expense):
Interest and dividend income, net	246	295	773	1,026
Gains on sale of assets			865
Gains (losses) on investments, net	4	2	36	(1,469)
Total other income (expense)	250	297	1,674	(443)
Net loss before income taxes	(145)	(4,266)	(5,948)	(13,857)
Income tax benefit		299		793
Net loss	$ (145)	$ (3,967)	$ (5,948)	$ (13,064)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.01)	$ (0.19)	$ (0.28)	$ (0.61)
Weighted average shares outstanding used to compute net loss per share:
Basic and diluted (in shares)	21,691	21,403	21,613	21,374